Scholar Rock Holding Corporation is a biopharmaceutical company focused on discovering, developing, and delivering therapies for spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company utilizes a proprietary platform to develop monoclonal antibodies that selectively target the latent, precursor forms of growth factors within the transforming growth factor beta (TGFβ) superfamily. Its lead product candidate, apitegromab, is an investigational fully human monoclonal antibody that inhibits myostatin activation to increase muscle mass and strength, with regulatory submissions filed in the U.S. and Europe for SMA. The pipeline also includes a subcutaneous formulation of apitegromab and SRK-439, a subcutaneously administered anti-myostatin antibody. Early-stage programs include SRK-181 for solid tumors, SRK-373 for fibrotic diseases, and SRK-256 for iron-restricted anemias. Scholar Rock was founded by scientists from Harvard Medical School and Boston Children’s Hospital, leveraging foundational discoveries in growth factor biology to address unmet medical needs in neuromuscular conditions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage scholarrock.com
Sector Healthcare IR page investors.scholarrock.com
Tags
neuromuscular diseases, spinal muscular atrophy, myostatin inhibition, monoclonal antibodies, rare diseases, muscular dystrophy, growth factor biology, subcutaneous formulations, apitegromab, SRK-439, SRK-181, SRK-373, SRK-256
Press page scholarrock.com/our-company/newsroom

Metrics

Valuation  
Market cap $ 5.071B
Market cap (USD) $ 5.071B
P/E -12.92
PEG —
P/BV 30.07
P/S 152.78
P/OCF -16.37
P/FCF -16.36
Dividend yield —
Turnover / mcap —
Returns  
ROE -123.1%
ROI -109.5%
ROIC -83.6%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 116.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 29
Quality score -53.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 0 — — 33.193M 18.816M 15.403M 20.492M 0 —
Net profit -377.939M -246.294M -165.789M -134.502M -131.799M -86.483M -51M -49.326M -24.995M
Free cash flow -300.637M -201.047M -145.297M -133.758M -132.037M -64.359M -66.23M 23.079M -22.098M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 44.05 43.22 18.8 9.05 24.84 48.53 13.18 22.97 —
Price performance 12m 0.02 1.3 1.08 -0.64 -0.49 2.68 -0.43 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 25M — — — — — 0.00
Borrowings, current (USD) — 641,000 438,000 — — 1.58M — 1.33M — —
Borrowings, non-current (USD) — 398,000 24,000 — 24.7M 48.4M 49.7M 48.7M 50.1M 99.7M
Lease liabilities (USD) — — — 5.3M 32.5M 27.1M 19.7M 11.8M 15M 9.21M
Cash and deposits (USD) 10.2M 56.5M 115M 36.3M 160M 213M 103M 102M 178M 324M
Right-of-use assets (USD) — — — 4.45M 32.3M 25.4M 18.5M 11.4M 15.6M 10.4M
Net debt (borrowings + leases - cash) (USD) — -55.8M -115M — -103M -136M -33.9M -40M -113M -215M
Cash flow detail
Operating cash flow (USD) — -21.7M 24.6M -63.1M -60.3M -127M -133M -145M -201M -300M
Purchases of property, plant and equipment (USD) — -361,000 -1.49M -3.12M -4.09M -5.25M -1.06M -71,000 -98,000 -602,000
Change in receivables (cash effect) (USD) — — — -25M 25M — — — — —
Change in payables (cash effect) (USD) — 636,000 1.66M -1.34M 2.1M 1.02M -251,000 -529,000 6.63M 208,000
Interest paid (cash effect) (USD) — -53,000 -34,000 — -251,000 -2.08M -4.37M -6.4M -6.62M -6.07M
Income taxes paid (cash effect) (USD) — — — — — — — — — -46,000
Share-based compensation (USD) — 1.48M 5.21M 7.97M 11.2M 23.1M 27.7M 27.1M 36.6M 75.6M
Operating cash flow before change in receivables (USD) — — — -38.1M -85.3M — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) — -22.1M 23.1M -66.2M -64.4M -132M -134M -145M -201M -301M
Income detail
Research and development expense (USD) — 19.9M 36.3M 54.2M 74.1M 108M 124M 122M 185M 208M
↳ 5y CAGR +44.2% +27.4% +27.8% +23.0%
Total comprehensive income (USD) — -25M -49.3M -51M -86.5M -132M -135M -165M -246M -378M
Comprehensive income to owners (USD) — -25M -49.3M -51M -86.5M -132M -135M -165M -246M -378M
Reported Aug 8, 2018 Mar 19, 2019 Mar 19, 2019 Mar 12, 2020 Mar 9, 2021 Mar 7, 2022 Mar 7, 2023 Mar 19, 2024 Feb 27, 2025 Nov 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following September 11, 2026 FDA approval

•ISEMBYLD shipped to specialty network prior to quarter-end, reflecting Q3 2026 ISEMBYLD revenue of $0.6 million

•Strong early patient and physician demand for ISEMBYLD, with initial patients infused in October 2026

•Apitegromab Marketing Authorisation Application (MAA) for treatment of children and adults living with SMA resubmitted to European Medicines Agency (EMA) and validated in October 2026; on track for Committee for Medicinal Products for Human Use (CHMP) opinion in H1 2027

•Apitegromab Japanese New Drug Application (JNDA) for treatment of children and adults living with SMA submitted to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and accepted under priority review

•Cash, cash equivalents, and marketable securities of $413.6 million as of September 30, 2026

•In November, reached definitive agreement to sell Priority Review Voucher (PRV) for $205 million; cash to be received upon closing

•Management to host a conference call today at 8:00 a.m.

Main content section

Scholar Rock to Present at Upcoming Investor Conferences

November 3, 2026

PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2026-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences:

  • UBS Global Biopharma Conference 2026: Scholar Rock is scheduled to participate in a fireside chat at 10:00 a.m. GMT / 5:00 a.m. ET on Monday, November 16, 2026 in London.

  • Jefferies Global Healthcare Conference 2026: Scholar Rock is scheduled to participate in a fireside chat at 4:00 p.m. GMT / 11:00 a.m. ET on Tuesday, November 17, 2026 in London.

A live webcast of the events will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcasts will be available for approximately 90 days.

About Scholar RockScholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide.

As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark and ISEMBLYD™ is a trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar RockInvestors and others should note that we communicate with our investors and the public using our company website, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X, or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103507217/en/

Scholar Rock Contacts Investors Laura Ekas, Ph.D. 917-439-0374 [email protected] Media Jeff Smith 682-401-8428 Molly MacLeod, Ph.D. 802-579-5995 [email protected]

Source: Scholar Rock

Primary Sidebar

Investor Menu

In this section

Select page... Investors & Media Press Releases Archived Press Releases Events & Presentations Corporate Governance Management Team Board of Directors Committee Composition Financials & Filings SEC Filings Stock Information Historical Stock Lookup Investment Calculator Analyst Coverage Investor FAQs Contact IR or Media

Footer

Scholar Rock, Inc. 301 Binney Street, 3rd Floor Cambridge, MA 02142

Phone: 857.259.3860 [email protected]

© 2026 All Rights Reserved

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

Scholar Rock, Inc. Logo

Main content section

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

October 20, 2026

PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 20, 2026-- Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open.

The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com.

To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.

An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

About Scholar RockScholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide.

As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar RockInvestors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X, or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020593796/en/

Scholar Rock Contacts

Investors Laura Ekas, Ph.D. 917-439-0374 [email protected]

Media Jeff Smith 682-401-8428 Molly MacLeod, Ph.D. 802-579-5995 [email protected]

Source: Scholar Rock

Primary Sidebar

Investor Menu

In this section

Select page... Investors & Media Press Releases Archived Press Releases Events & Presentations Corporate Governance Management Team Board of Directors Committee Composition Financials & Filings SEC Filings Stock Information Historical Stock Lookup Investment Calculator Analyst Coverage Investor FAQs Contact IR or Media

Footer

Scholar Rock, Inc. 301 Binney Street, 3rd Floor Cambridge, MA 02142

Phone: 857.259.3860 [email protected]

© 2026 All Rights Reserved

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

Scholar Rock, Inc. Logo

Prompts

Scholar Rock Holding Corporation (ticker SRRK), listed in United States.

ETFs Holding Scholar Rock Holding Corporation

ETF Weight in ETF Shares Market value As of
HRTS 0.63% 6,177 $ 350.854K Aug 31, 2026
MMSC 0.50% 5,608 $ 249.78K Nov 16, 2026
TMSL 0.33% 164,229 $ 9.033M Jun 30, 2026
RUSC 0.33% 4,785 $ 263.175K Jun 30, 2026
FSEG 0.28% 288 $ 15.84K Jun 30, 2026
ESSC 0.23% 1,785 $ 84.422K Jul 31, 2026
FTKI 0.23% 1,328 $ 59.149K Nov 16, 2026
RESM 0.17% 112 $ 6,160.00 Jun 30, 2026
MKTN short -0.15% -2,819 $ -155.045K Jun 30, 2026
FBCG 0.05% 79,589 $ 3.764M Jul 31, 2026
MSSM 0.03% 3,669 $ 208.399K Aug 31, 2026
FESM 0.03% 29,652 $ 1.631M Jun 30, 2026
VFMO 0.02% 7,840 $ 445.312K Aug 31, 2026